Home > Oncology > ELCC 2019 > Trials: Immunotherapy in Stage 4 Lung Cancer > Post-study immunotherapy in MYSTIC

Post-study immunotherapy in MYSTIC

Presented By
Dr Niels Reinmuth, Asklepios Lung Clinic, Munich-Gauting, Germany
ELCC 2019
Phase 3, MYSTIC
Durvalumab is approved for the treatment of unresectable, stage 3 NSCLC and has shown clinical activity in heavily pre-treated patients with metastatic NSCLC in phase 2 and 3 trials [1,2]. MYSTIC is an open-label, phase 3 study evaluating first-line durvalumab with or without tremelimumab vs platinum-based chemotherapy in metastatic NSCLC. In a previous analysis, presented at the 2018 ESMO I-O meeting, an improvement in OS was seen with durvalumab vs chemotherapy in patients with tumour cell PD-L1 expression ≥25% (see Figure; HR 0.76, P=0.036) [3]. The safety and tolerability profile of durvalumab was consistent with data from previous trials [1,2,4]. Figure: OS in patients with PD-L1 expression of ≥25%: primary endpoint of MYSTIC trial [3] Figure kindly provided by Dr ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on